ID   MCF3B
AC   CVCL_M373
DR   cancercelllines; CVCL_M373
DR   Wikidata; Q54904448
RX   PubMed=11079502;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=RGD; 69267; Slc5a5.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-09-24; Version: 18
//
RX   PubMed=11079502;
RA   Nakamoto Y., Saga T., Misaki T., Kobayashi H., Sato N., Ishimori T.,
RA   Kosugi S., Sakahara H., Konishi J.;
RT   "Establishment and characterization of a breast cancer cell line
RT   expressing Na+/I-symporters for radioiodide concentrator gene
RT   therapy.";
RL   J. Nucl. Med. 41:1898-1904(2000).
//